RATING

RECOMMENDATION

Sell

  • ROFR Required
  • Available in Depository:

  • NSDL

  • CDSL

  • Available for Investment:

  • Primary

  • Secondary

RATING

RECOMMENDATION

Sell

Business Type

Dominant Leader

RATING

RECOMMENDATION

Sell

Business Type

Dominant Leader

Discover and get complete analyzed report on Pharmeasy Pre IPO shares - Management, Business Model, Financials, Pharmeasy Revenue Growth, Valuations, Funding Rounds, PharmEasy News and latest updates on PharmEasy Share Price.

ISIN

INE0DJ201029

Face Value

₹1.00

Total Share

6,09,81,09,930

Total Income

₹2,360.66 Cr

Profit After Tax

-₹641.34 Cr

EPS

-₹206.77

P/E

-0.23

P/B

15.30

Market Capitalisation

₹29,270.93 Cr

Enterprise Value

₹29,776.09 Cr

Book Value

₹3.14

Earnings Yield

-430.77 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Pre IPO

Cashflow - Operations

-₹813.68 Cr

Cashflow - Financing

₹1,019.02 Cr

Pharmeasy Growth

Compounded Sales Growth

  • 249.83%

    1 Year

Pro Only

Compounded Profit Growth

  • NA

    1 Year

Pro Only

Return On Equity

  • -33.51%

    2021

Pro Only

About Pharmeasy

  • API Holdings Limited, through its subsidiaries, develops and operates an integrated digital healthcare platform. The company offers teleconsultation; diagnostics and radiology tests; and RedBook, an enterprise resource planning (ERP) and customer relationship management software for pharmacies. 
  • The company operates a consumer healthcare app called PharmEasy which enables on demand, home delivery of pharmaceutical products to the customers.
  • It also provides call center management, medical and legal transcription, data processing, warehousing, and database management services.
  • In addition, the company offers pharmaceutical, medical, and health care products; nutraceutical products; generic drugs; and dietary and food supplements, as well as surgical instruments and equipment.
  • Further, it deals, buys, and sells computer hardware, computer systems, and assemble data processors. Additionally, the company engages in the wholesale and retail of pharmaceuticals, antibiotics, drugs, medicines, biologicals, nutraceuticals, healthcare, ayurvedic, and dietary supplement products; medicinal preparations and vaccines; and wellness and health related products.
  • It serves pharmacies, hospitals, clinics, and doctors
  • The company has grown a lot since its inception and presently, in 2021, has 26 subsidiaries including Aknamed, Docon and Thyrocare.
  • API Holdings is the holding entity for the PharmEasy group. API Holding was incorporated on March 31, 2019 and heads its operations from its office in Mumbai, Maharashtra.

  • Pharmeasy IPO Details

API Holdings Limited has filed its DRHP on 8th November 2021 and will be coming out with their IPO in this financial year.

According to the DRHP the entire IPO only consists of a fresh issue, which means that none of the existing shareholders of the company are selling their stake in the company. Their decision to not to cash out during the IPO indicates confidence among company’s investors about the growth potential of the company.

The company may also consider a further issue of equity shares via a private placement of up to ₹1250 crore as mentioned in their DRHP.

Pharmeasy
Fresh Issue

₹ 6250.00 Cr

Pharmeasy
Total IPO Size

₹ 6250.00 Cr

  • Pharmeasy Funding

Funded By Funding Amount Date of Investment Funding Round Fund Name
VestinWolf Capital Management Undisclosed 01 Nov 2021 - Private Equity Round
Trifecta Capital Advisors Undisclosed 20 Oct 2021 - Debt Financing
IIFL Finance $ 146 M 18 Oct 2021 Secondary -
Steadview Capital $ 204 M 18 Oct 2021 - Venture Round
Arokiaswamy Velumani $ 500 M 07 Jul 2021 - -
B Capital Group $ 20 M 17 Jun 2021 Secondary -
Prosus Ventures, TPG Growth $ 390 M 07 Apr 2021 Series E -
Temasek Holdings $ 220 M 27 Nov 2019 Series D -
Eight Roads Ventures India $ 50 M 26 Sep 2018 Series C -
InnoVen Capital ₹ 450 M 11 Sep 2018 - Debt Financing
  • Pharmeasy Merger & Acquisition

Acquisition

  • Docon Technologies Private Limited (the “Acquirer”), a wholly owned subsidiary of API Holdings entered into a share purchase agreement dated June 25, 2021 for the purchase of 34,972,999 equity shares of Thyrocare aggregating to 66.14% of the equity share capital for an aggregate consideration of ₹ 45,464.90 million. Further, the Acquirer made an open offer to the shareholders of Thyrocare for acquisition of upto 13,755,077 equity shares of Thyrocare and ended up acquiring 2,683,093 equity shares at a price of ₹ 1,300 per equity share, aggregating to 5.07% of the equity share capital. The transaction was consummated on September 2, 2021, being the date when the company acquired the control of Thyrocare.
  • On 19th August 2021, API Holdings(Pharmeasy) acquired 12,04,133 equity shares and 9,75,925 equity shares of Aknamed for a consideration of ₹3,687.00 million and ₹3,080.00 million respectively. Further, the company purchased 76,075 equity shares of Aknamed through a share purchase agreement dated August 19, 2021 from certain angel investors. API Holdings(Pharmeasy) has made this acquisition to position itself as a broader online healthcare firm, diversifying from being just an online medicine delivery platform.
  • The company purchased 2,440,057 securities of Medlife International Private Limited from Ananth Sankaranarayanan, Prasid Uno Family Trust, Ananth Sankaranarayanan Family Trust, Matrix Partners India Investments Holdings II, LLC, Matrix Partners India Investments II Extension, LLC, Times Internet Limited, Dream Incubator Inc. (“Medlife Shareholders”) for an aggregate consideration of ₹ 10,827.61 million provided under the Medlife SPA by way of issue of 17,94,588 CCPS XVI, 1,29,023 CCPS XVII and 9,544 CCPS XVIII of our Company to Medlife Shareholders in accordance with the securities subscription agreement dated December 16, 2020. Further, as part of the Medlife SPA, the Company entered into CCD agreement dated December 16, 2020 with Ivy Icon Solutions LLP for transferring the existing compulsorily convertible debentures held by Ivy Icon in Medlife International Private Limited in consideration of issuance of CCDs to Ivy Icon by our Company. 

Investments

  • On October 14, 2021, the company acquired 49.17% of the equity share capital of Marg ERP Limited for a consideration of ₹ 2,548.00 million. Marg is into the business of B2B Pharma, software and solutions.
  • On August 10, 2021, the company acquired 19.99 % of the equity share capital of Aarman Solutions Private Limited for a consideration of ₹ 99.95 million. Aarman is the 100 % owner of Axelia Solutions Private Limited, the entity which operates the PharmEasy marketplace. 
  • Pharmeasy Subsidiaries

  • Medlife Wellness Retail Private Limited
  • Akna Medical Private Limited
  • Ascent Wellness and Pharma Solutions Private Limited
  • Shell Pharmaceutical
  • Threpsi Solutions Private Limited
  • Aycon Graph Connect Private Limited
  • ARZT and Health Private Limited
  • Docon Technologies Private Limited
  • AHWSPL India Private Limited
  • Instinct Innovations Private Limited
  • Ayro Retail Solutions Private Limited
  • Avighna Medicare Private Limited
  • D. C. Agencies Private Limited
  • Desai Pharma Distributors Private Limited
  • Eastern Agencies Healthcare Private Limited
  • VPI Medisales Private Limited
  • Aarush Tirupati Enterprise Private Limited
  • AKP Healthcare Private Limited
  • Aryan Wellness Private Limited
  • Aushad Pharma Distributors Private Limited
  • Dial Health Drug Supplies Private Limited
  • Mahaveer Medi-Sales Private Limited
  • Reenav Pharma Private Limited
  • Venkatesh Medico Private Limited
  • Muthu Pharma Private Limited
  • Pearl Medicals Private Limited
  • Rau and Co Pharma Private Limited
  • Metarain Distributors Private Limited
  • Allumer Medical Private Limited
  • Shreeji Distributors Pharma Private Limited
  • Vardhman Health Specialities Private Limited
  • Cosaintis Products Private Limited
  • Healthchain Private Limited
  • Supplythis Technologies Private Limited
  • Nueclear Healthcare Limited
  • Thyrocare Technologies Limited

Pharmeasy Business Model

  • Medlife Wellness Retail Private Limited operates as a healthcare company. The Company offers online medicines, wellness products, book doctor consultation.
  • Akna Medical Private Limited is a hospital-focused supply chain platform, enabling hospitals to simplify, optimise and monitor procurement and consumption using a cloud-based technology platform, national infrastructure and a complete product basket.
  • Ascent Wellness and Pharma Solutions Private Limited a pharma supply chain company focused at automation and innovation in backend processes to improve  accessibility and affordability of effective healthcare for all.
  • Shell Pharmaceutical is a Haryana based pharmaceutical company ,established in 1995, with the vision of making high quality medicines. Shell Pharmaceutical is a research driven forward looking pharmaceutical company with expertise in development of various finished dosage.


  • Pharmeasy Revenue Segmentation

  • Distribution to retailers
  • Distribution to chemists/institution
  • Services of delivery
  • Other revenue
  • Pharmeasy Product & Services

  • Prescription/OTC pharmaceuticals
  • Consumer healthcare products
  • Comprehensive diagnostic test services
  • Teleconsultations
  • Pharmeasy Assets

  • The company owns INR 202.53 million worth of office equipment.
  • The company owns INR 219.37 million worth of computer and hardware.
  • The company has recently added INR 31.01 million of plant and machinery increasing it's total holding to INR 36.72 million.
  • Pharmeasy Industry Overview

Industry Statistics

  • The healthcare sector consists of businesses that provide medical services, manufacture medical equipment or drugs, provide medical insurance, or otherwise facilitate the provision of healthcare and pharmaceuticals to patients.
  • India’s domestic pharmaceutical market has an estimated value of US$ 42 billion in 2021. The industry's growth rate in the last decade was 8.5% and has been lower at 6.2% over the past five years. Despite the fall in growth rate of the pharmaceutical industry over past five years, factors that have lead to recent improvement in growth rate include expansion to new geographies, widening the coverage of pharma and over the counter products sold by the company, improved delivery times etc.
  • Apart from over the counter sales, a new trend that has been seen in the pharmaceutical industry is the online sale of pharmaceuticals. The online pharmacy market in India has been growing rapidly and the prevalent pandemic conditions acting as a catalyst to its growth. The online pharmacy market is currently valued at $360 million in 2021.
  • The online pharmacy market has grown because of factors like increased smartphone penetration which as per projections by RedSeer will comprise of 52-59% of India’s population, favorable government initiatives towards digitization, shift in preference towards online shopping which can be seen by the number of online shoppers increasing from 120-150 million in 2019 to 160-180 million in 2020 as per RedSeer, consumers trusting online brands to deliver original products etc. Another major factor increasing the growth of the entire pharmaceutical industry, both online and offline, was the huge surge in Covid-19 pandemic witnessed by the country. 
  • The regulations in the industry include Draft Drugs and Cosmetics rule 2018, Drugs and Cosmetics act 1940, Drugs and Cosmetics rules 1945, Pharmacy Act 1948, The Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954.
  • Competitors of the company include NetMeds, Practo, 1mg, Apollo Pharmacy etc.

Future Prospects

  • India’s domestic pharmaceutical market is estimated at US$ 42 billion in 2021 and likely to reach US$ 65 billion by 2024 and further expand to reach US$ 120-130 billion by 2030.
  • According to EY, the online pharmacy market in India is estimated to reach $2.7 billion by 2023 from $360 million which it is currently at in 2021
  • Medicine spending in India is projected to grow 912% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.

Government Initiatives

  • In June 2021, Finance Minister Ms. Nirmala Sitharaman announced an additional outlay of Rs. 197,000 crore (US $26,578.3 million) that will be utilised over five years for the pharmaceutical PLI scheme in 13 key sectors such as active pharmaceutical ingredients, drug intermediaries and key starting materials.
  • The Digital India Program was started by the government in 2015 to digitally connect every corner of India including the rural areas and remote villages with high speed internet. The aim of this campaign was to empower citizens to gain knowledge and use the government services easily and to make people interact with the government. Over the years this program has increased the number of online users to a large extent and has helped online businesses in increasing their consumer base.
  • Under Union Budget 2021-22, the Ministry of Health and Family Welfare has been allocated Rs. 73,932 crore (US$ 10.35 billion) and the Department of Health Research has been allocated Rs. 2,663 crore (US$ 365.68 billion). The government allocated Rs. 37,130 crore (US$ 5.10 billion) to the 'National Health Mission’.
  • To achieve self-reliance and minimise import dependency in the country's essential bulk drugs, the Department of Pharmaceuticals initiated a PLI scheme to promote domestic manufacturing by setting up greenfield plants with minimum domestic value addition in four separate ‘Target Segments’ with a cumulative outlay of Rs. 6,940 crore (US$ 951.27 million) from FY21 to FY30.
  • PM Aatmanirbhar Swasth Bharat Yojana was allocated Rs. 64,180 crore (US$ 8.80 billion) over six years. The Ministry of AYUSH was allocated Rs. 2,970 crore (US$ 407.84 million), up from Rs. 2,122 crore (US$ 291.39 million). This will assist healthcare related service industries to grow in the long run.

Pharmeasy Awards & Achievements

  • Pharmeasy has been selected in the list of top 100 Most Promising Brands in India 2016 and has been rated as the most admired brand in the healthcare category in the country.
  • The founders of Pharmeasy, Dhaval Shah and Dharmil Sheth, were named in Forbes 30 under 30 list on 17 February 2017.
  • The company was the winner of the second annual CB Insights Digital Health 150 in 2020.

Pharmeasy Strengths

  • The company has a first mover advantage in the industry due to which it has captured a wider market than any of it's peers. This first mover advantage has also helped pharmeasy to establish a strong brand name in the market.
  • The revenue of the company has grown by a massive 220% in FY'21 over FY'20 which was majorly due to a huge surge in the demand for pharmaceuticals and healthcare products as a result of rise in pandemic.
  • The company has recently entered into the diagnostic test provision services segment, which has allowed it to tap a larger market due to increased awareness on self care and precaution as a result of the widespread pandemic in the country.

Pharmeasy Shortcomings

  • The company's total debt has increased by 120% in FY'21 over FY'20 which is will negatively impact the solvency position of the company and will hamper growth in the long run.
  • The cash and cash equivalents of the company has increased massively from INR 58 Cr. to INR 323 Cr. in FY'21. The company should look to invest in areas where they can earn a higher return.
  • The company has accustomed its customers to large discounts on pharmaceuticals round the year. This will make it harder for the company to earn a higher return even in the future years.

Pharmeasy Opportunities

  • The company should look to diversify into live online counselling with health experts. With the world looking towards a shift in the work culture and new normal, people are looking to get health consultations too from anywhere. The company should look to take this opportunity as a step towards the future.

Pharmeasy Threats

  • Even though the revenue of the company has grown massively, the company has not been able to convert the higher revenues to profits and further the losses of the company have increased massively instead. This is harmful for growth in the long run.
  • The company faces stringent competition from its competitors in the market, who have despite of making a recent entry are putting in full force to emerge as leaders in the market.
  • The company has raised a lot of money as debt but has still not attained profitability in FY'21. The company's solvency will be at risk if they do not increase their profitability in the near future.
Pharmeasy Rating

  • RECOMMENDATION

    Sell

  • Pharmeasy Detail Info

Industry Statistics

PUBLIC LIMITED

Registered In

India

last Updated

27/11/2021

Registered Date

31/03/2019

Planify Ticker

PHA

Reg Office: 902, 9th Floor, Raheja Plaza 1, B-Wing, Opposite R-City Mall, L.B.S Marg, Ghatkopar (W), Mumbai, Mumbai City, Maharashtra.

Visit Website

Frequently Ask Questions

(Pharmeasy) API Holdings Limited has filed its DRHP on 8th November 2021

The face value of the company is 1

Right now the company is making heavy losses and it will take some years for the company to be profitable

Naspers Ventures BV, Macritchie Investments Pvt Ltd., Universal Trustees Pvt Ltd are the major shareholders of the Pharmeasy 

Naspers Ventures BV, Macritchie Investments Pvt Ltd., Universal Trustees Pvt Ltd are the major shareholders of the Pharmeasy 

Siddharth Shah is the Founder, Managing Director and Chief Executive Officer of the company

The company has a first mover advantage in the industry due to which it has captured a wider market than any of it's peers. This first mover advantage has also helped pharmeasy to establish a strong brand name in the market.

We recommend See rating on this company

The company had a loss of 641 Crores

Please find below the procedure for buying stock_name_auto Unlisted Shares at Planify.
• 1. You confirm booking of stock_name_auto Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling stock_name_auto Unlisted Shares is 6 months after listing. Hence you can’t sell stock_name_auto Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

Please find below the procedure for selling stock_name_auto Unlisted Shares at Planify.
• 1. We will confirm our buying price of stock_name_auto Unlisted Shares.
• 2. We will give you our client master report and you will transfer the stock_name_auto Unlisted Shares to our demat account.
• 3. We will ask for bank details of yours once the stock_name_auto Unlisted Shares are received in our demat account..
• 4. We will transfer the funds in your bank account within 24 hrs of receiving the stock_name_auto Unlisted Shares.
• 5. Payment will be made in RTGS / NEFT / CHEQUE TRANSFER/IMPS. No CASH DEPOSIT.
• 6. Payment will be given in the same account which is linked to demat account or you need to provide the cancelled cheque shows your name to verify. As per SEBI regulations, the transfer of funds in the third party account is not legal and our policy refrain us from doing so.
Note: The price at which we are buying the share is fixed for 3 days. If you cant sell your stock within 3 days, then the price of that day will be applicable when we receive shares in our demat.

Lock-in period of stock_name_auto Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of stock_name_auto Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of stock_name_auto Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

DIS - Delivery Instruction Slip is the way through which an investor can sell or transfer the stock_name_auto Unlisted Shares from his/her demat account to any other demat account. There are two Types of DIS Slip.
1. Offline-DIS - This is an offline mode of transfer of shares wherein the investors needs to fill DIS form and give it to their broker for transferring the shares. Following are the fields which are required to be filled.
• a. ISIN number of stock_name_auto Unlisted Shares.
• b. Name of stock_name_auto Unlisted Shares
• c. Quantity of stock_name_auto Unlisted Shares
• d. Cosideration Amount
• e. Target DP ID and Client ID
• f. Annexure
2. Online DIS - Some of the broker these days gives facility of transferring the stock_name_auto Unlisted Shares via online DIS. So, please check with your broker whether such facility is available or not. For example: Angel Broking proivdes the facility of Online-DIS from its platform. As an investor he/she simply needs to add a beneficiary into it and send the stock_name_auto Unlisted Shares by filling the details similar to Ofline-DIS.

In the last 4-5 years, the unlisted share market has become quite big and as a result of that, the ticket size has reduced from usual 5-10 Lac to 35-50k in today's scenario. So, via our Planify platform, if somebody wants to buy stock_name_auto Unlisted Shares then minimum investment would be 35-50k.

Yes, buying and selling of unlisted shares in India is 100% legal.

If you sell your shares within 2 years, then you will have to pay Short-term Capital gain on unlisted shares. Short-Term Capital Gain is added in your Income. So, as per individual tax slab you need to pay capital gain tax.

If you sell your shares after 2 years, then you will have to pay Long-term Capital gain on unlisted shares LTCG is 20% with indexation benefits.

Taxes will remain the same irrespective of listing of shares, if bought in unlisted market. Actually, to be eligible for taxes as per listed market, one has to pay STT on buying and selling of shares. But, if you buy in unlisted and sell in listed market, one pay STT only on selling so, taxes of listed market will not be applicable.

If you buy stock_name_auto Unlisted Shares from Planify then these shares can checked in two ways. However, before we tell you the process of checking of shares, it is intimated that as per SEBI regulations, the shares can be transferred in demat account only.
Check credit of stock_name_auto Unlisted Shares Instantly?
• 1.You can download the NSDL or CDSL application from google play-store and check. If you want to check whether your stock broker is registered with NSDL or CDSL then check the following procedure.
• By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
• Demat Account = DP ID + Client ID. (16 Characters )
• "DP ID is the unique identification of the Broker. Every broker gets a unique number from CDSL or NSDL.By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
• Client ID is the unique identification of the Client. Every client gets this unique number which represents his/her portfolio.
• In CDSL, all these characters are numbers (1234567891234567) first 8 digits are DP ID and next 8 digits are Client Id whereas in NSDL the first two characters are letters which are in accordance with the country that you are from (IN12345678912345), then 6 unique digits for Broker and next 8 digits are client ID.
• Example:
• CDSL = 12345678(DP ID) and 91234567(Client ID).
• NSDL = IN123456 (DP ID) and 78912345(Client ID).
• Check in brokers application?
• Credit of stock_name_auto Unlisted Shares can be checked in brokers application as well but it takes T+2 days to show the shares.

The stock_name_auto Unlisted Shares are credited in demat account same day of transferring funds in our company's bank account.

The price of stock_name_auto Unlisted Shares can be checked in two ways. First, you can join our telegram channel where on daily basis we share the latest prices of all the unlisted shares in the morning and secondly, you can register on Planify.live platform to see the historical graphs and prices of all the shares at one place.

If you see the thesis of investment in the unlisted shares then it is being done mainly to take the advantage of IPO market. And, if the IPO plans of company get delayed due to market conditions or any other reason then demand suddenly drops in the market. The unlisted market works mainly on demand and supply and if there is no IPO news then getting exit would be difficult.

"Planify is India's fastest and leading marketplace to buy and sell unlisted shares. In the last 3 years, we have already served more than 1 million users on the platform. The total transactions value done from the platform is already more than 100 Crores. The name of our Co-founders Mr. Umesh Paliwal and Dinesh Gupta publish regularly in leading newspapers like MoneyControl, Business-Standard, ET etc for their views on IPO and Unlisted market. In the last 3 years, Planify has made a good name for itself in the industry and gained a trust of their users. So, the new investors should not be worried about any kind of fraud that is mostly happens with unkown brokers in the market while doing investment with Planify."

We at Planify do the valuation based on 2 methods.
• 1. We check the last funding that is being done in the stock_name_auto Unlisted Shares to ascertain the benchmark valuation.
• 2. If there is no funding happened in the company, then we try to find a business similar to stock_name_auto Unlisted Shares in the listed space and do comparison method to ascertain the valuation.
As an investor in the unlisted space, we would always recommend that you must check all the risk parameter carefully before investing in the unlisted space.

We source shares either from the employees or initial investors looking to liquidate their stock_name_auto Unlisted Shares.

Pre-IPO shares means which are planning for an IPO in near future. So, all the shares which are traded on the platform are not Pre-IPO Shares. However, if the company's business is going good and then demand will always be there in the unlisted space, so even if the IPO does not come, the investors can easily liquidate their stock_name_auto Unlisted Shares in the unlisted market itself.

Rules and regulations of SEBI are applicable in the Unlisted space like lock-in period of 6 months, paying of Stamp Duty, and DP Charges for every transaction etc. However, to become an unlisted broker there is no such regulation by SEBI as of yet.

For tracking news and other information about stock_name_auto Unlisted Shares, one can visit our website wherein we post news and other information on daily basis and one can also join our telegram channel.

Fundamental & Comparative valuation models and the forces of demand and supply in the market for unlisted shares dictate the price. These prices are based on our estimates and transaction history of stock_name_auto Ltd unlisted share.

We can generally arrange lot sizes starting with an investment of INR 20,000. To confirm the lot sizes of stock_name_auto Ltd unlisted shares with us.

The financials of stock_name_auto Ltd which includes the P/L of stock_name_auto Ltd and the Balance Sheet of stock_name_auto Ltd is in the financials section.

The annual report of stock_name_auto Ltd is available in the annual report section.